NCT04853992 - Trial to Assess the Efficacy and Safety of LEO 152020 in Adult Patients With Cholinergic Urticaria | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

July 8, 2022

Study Completion Date

July 11, 2022

Conditions

Cholinergic Urticaria

Interventions

DRUG

LEO 152020

LEO 152020 is a small drug molecule which can block the histamine 4 receptor (H4R). LEO 152020 is a tablet for oral administration.

DRUG

LEO 152020 placebo

LEO 152020 placebo is a tablet for oral administration. LEO 152020 placebo contains the same excipients in the same concentration as the LEO 152020 tablet, except the medical ingredient, LEO 152020.

Trial Locations (6)

10117

LEO Investigational Site, Berlin

24105

LEO Investigational Site, Kiel

52074

LEO Investigational Site, Aachen

79104

LEO Investigational Site, Freiburg im Breisgau

80802

LEO Investigational Site, München

01307

LEO Investigational Site, Dresden